Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Marimastat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 known ✓ | P03956 | 9/20 | 1.00 |
| ▸ | MMP2 known ✓ | P08253 | 8/20 | 1.00 |
| ▸ | MMP3 known ✓ | P08254 | 6/20 | 1.00 |
| ▸ | MMP9 known ✓ | P14780 | 5/20 | 1.00 |
| ▸ | MMP7 known ✓ | P09237 | 3/20 | 1.00 |
| ▸ | MMP12 known ✓ | P39900 | 1/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 13/20 | 1.00 |
| ▸ | MMP8 | P22894 | 6/20 | 1.00 |
| ▸ | MMP13 | P45452 | 3/20 | 1.00 |
| ▸ | TNF | P01375 | 2/20 | 1.00 |
| ▸ | MMP20 | O60882 | 1/20 | 1.00 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 1.00 |
| ▸ | MMP10 | P09238 | 1/20 | 1.00 |
| ▸ | MMP14 | P50281 | 1/20 | 1.00 |
| ▸ | MMP15 | P51511 | 1/20 | 1.00 |
| ▸ | MMP16 | P51512 | 1/20 | 1.00 |
| ▸ | MMP25 | Q9NPA2 | 1/20 | 1.00 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 1.00 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 1.00 |
| ▸ | MMP24 | Q9Y5R2 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Marimastat SCHEMBL31231856 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL1821430 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL13575773 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL8189167 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL34033 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL13253251 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL8193003 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL17799241 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL20793036 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL7931107 | 0.99 | ADAM17 (0.97) | ADAM17MMP1MMP2MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110828-B1 | CONTINUOUS FLOW PEPTIDE SYNTHESIS | UNIV SZEGEDI (HU) | 2020-12-09 | — | — | EP | claimed |
| US-20180000817-A1 | TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME AND DISEASES RELATED TO VASCULAR AGEING | Biocant - Associação De Transferência De Tecnologia (PT) | 2018-01-04 | — | — | US | claimed |
| EP-3244883-A1 | TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME AND DISEASES RELATED TO VASCULAR AGEING | Biocant - Associação De Transferência De Tecnologia (PT) | 2017-11-22 | — | — | EP | claimed |
| WO-2016113713-A1 | TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME AND DISEASES RELATED TO VASCULAR AGEING | Biocant - Associação De Transferência De Tecnologia (PT) | 2016-07-21 | — | — | WO | claimed |
| US-20120058140-A1 | TOPICAL COMPOSITIONS FOR INHIBITING MATRIX METALLOPROTEASES AND PROVIDING ANTIOXIDATIVE ACTIVITIES | BATH & BODY WORKS BRAND MANAGEMENT, INC. (US) | 2012-03-08 | — | — | US | claimed |
| EP-4478049-A2 | CANCER MODELING PLATFORMS AND METHODS OF USING THE SAME | Wake Forest University Health Sciences (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-3494207-B1 | CANCER MODELING PLATFORMS AND METHODS OF USING THE SAME | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20240192194-A1 | CANCER MODELING PLATFORMS AND METHODS OF USING THE SAME | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2024-06-13 | — | — | US | disclosed |
| US-11047847-B2 | Methods and apparatus for modeling cancer metastasis in vitro | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3356512-B1 | METHODS AND APPARATUS FOR MODELING CANCER METASTASIS IN VITRO | WAKE FOREST UNIV HEALTH SCIENCES INC (US) | 2021-03-31 | — | — | EP | disclosed |
| US-20200087648-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | NYSNOBIO IRELAND DAC (IE) | 2020-03-19 | — | — | US | disclosed |
| US-20190187129-A1 | CANCER MODELING PLATFORMS AND METHODS OF USING THE SAME | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2019-06-20 | — | — | US | disclosed |
| US-20180000817-A1 | TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME AND DISEASES RELATED TO VASCULAR AGEING | Biocant - Associação De Transferência De Tecnologia (PT) | 2018-01-04 | — | — | US | disclosed |
| EP-3244883-A1 | TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME AND DISEASES RELATED TO VASCULAR AGEING | Biocant - Associação De Transferência De Tecnologia (PT) | 2017-11-22 | — | — | EP | disclosed |
| WO-2016113713-A1 | TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME AND DISEASES RELATED TO VASCULAR AGEING | Biocant - Associação De Transferência De Tecnologia (PT) | 2016-07-21 | — | — | WO | disclosed |
| EP-2926808-A1 | USE OF METALLOPROTEASE INHIBITORS FOR THE TREATMENT OF POLYCYSTIC LIVER DISEASES | Administración General De La Communidad Autónoma De Euskadi (ES) | 2015-10-07 | — | — | EP | disclosed |
| US-8847003-B2 | Role of proteoglycans in drug dependence | SANNA PIETRO P (US) | 2014-09-30 | — | — | US | disclosed |
| US-8435541-B2 | Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities | BATH & BODY WORKS BRAND MANAGEMENT, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120058140-A1 | TOPICAL COMPOSITIONS FOR INHIBITING MATRIX METALLOPROTEASES AND PROVIDING ANTIOXIDATIVE ACTIVITIES | BATH & BODY WORKS BRAND MANAGEMENT, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058140-A1 | TOPICAL COMPOSITIONS FOR INHIBITING MATRIX METALLOPROTEASES AND PROVIDING ANTIOXIDATIVE ACTIVITIES | TIMP3, MMP1, MMP9 | MMP1 2/4885MMP2 6/4885MMP3 10/4885 |
| US-20200087648-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | PINK1, XIAP, STUB1 | MMP1 3207/4885MMP2 2913/4885MMP3 3156/4885 |
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | MMP17, MMP25, TIMP3 | MMP1 16/4885MMP2 7/4885MMP3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.